Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.63 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 18/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970515 | 0.95 | MAP4K4 (0.69) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL6113916 | 0.88 | S1PR1 (0.63) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL3741047 | 0.88 | S1PR1 (0.73) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL8283256 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1965871 | 0.85 | MAP4K4 (0.67) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL1966179 | 0.84 | MAP4K4 (0.63) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL6113510 | 0.83 | S1PR1 (0.78) | S1PR1S1PR3S1PR5 | |
| SCHEMBL12582161 | 0.82 | S1PR1 (0.61) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL2543134 | 0.81 | MAP4K4 (0.56) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL1420770 | 0.81 | S1PR1 (0.78) | MAP4K4MINK1PRKCDS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-2091950-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | MAP4K4 2086/4885MINK1 1160/4885PRKCD 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.